Abstract
Mood disorders in general, and bipolar disorder in particular, are unique among the psychiatric conditions in that they are associated with extraordinarily high rates of comorbidity with a multitude of psychiatric and medical conditions. Among all the potential cormobidities, co-occurring anxiety disorders stand out due to their very high prevalence. Outcome in bipolar illness is worse in the presence of a comorbid anxiety disorder. The coexistence of an anxiety disorder presents a particularly difficult challenge in the treatment of bipolar illness since antidepressants, the mainstay of pharmacologic treatments for anxiety, may adversely alter the course of manic-depression. Identification of anxiety disorders in bipolar patients is important. The treatment plan needs to balance the potential benefit and harm of antidepressant administration.
Similar content being viewed by others
References
Maremmani I, Perugi G, Pacini M, et al.: Toward a unitary perspective on the bipolar spectrum and substance abuse: opiate addiction as a paradigm. Journal of Affective Disorders 93(1–3):1–12, 2006
McElroy SL, Kotwal R, Keck PE Jr, et al.: Comorbidity of bipolar and eating disorders: distinct or related disorders with shared dysregulations? Journal of Affective Disorders 86(2–3):107–127, 2005
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders-Text Revision, ed 4, revised. Arlington, VA, American Psychiatric Association, 2000
Merikangas KR, Akiskal HS, Angst J, et al.: Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Archives of General Psychiatry 64(5):543–552, 2007
Angst J, Gamma A, Benazzi F, et al.: Toward a re-definition of subthreshold bipolarity: epidemiology and proposed criteria for bipolar-II, minor bipolar disorders and hypomania. Journal of Affective Disorders 73(1–2):133–146, 2003
Tohen M, Strakowski SM, Zarate C Jr, et al.: The McLean–Harvard first-episode project: 6-month symptomatic and functional outcome in affective and nonaffective psychosis. Biological Psychiatry 48:467–476, 2000
Tohen M, Zarate CA Jr, Hennen J, et al.: The McLean–Harvard first-episode mania study: Prediction of recovery and first recurrence. American Journal of Psychiatry 160:2099–2107, 2003
Murray CJL, Lopez AD (eds): The global burden of disease and injury series, volume 1: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge, MA, Harvard University Press, 1996
Martinez-Aran A, Vieta E, Torrent C, et al.: Functional outcome in bipolar disorder: the role of clinical and cognitive factors. Bipolar Disorders 9(1–2):103–113, 2007
Conus P, Cotton S, Abdel-Baki A, et al.: Symptomatic and functional outcome 12 months after a first episode of psychotic mania: barriers to recovery in a catchment area sample. Bipolar Disorders 8:221–231, 2006
DelBello MP, Hanseman D, Adler CM, et al.: Twelve-month outcome of adolescents with bipolar disorder following first hospitalization for a manic or mixed episode. American Journal of Psychiatry 164:582–590, 2007
Sareen J, Cox BJ, Afifi TO, et al.: Anxiety disorders and risk for suicidal ideation and suicide attempts: a population-based longitudinal study of adults. Archives of General Psychiatry 62:1249–1257, 2005
Rodriguez BF, Bruce SE, Pagano ME, et al.: Relationships among psychosocial functioning, diagnostic comorbidity, and the recurrence of generalized anxiety disorder, panic disorder, and major depression. Journal of Anxiety Disorders 19:752–766, 2005
Weissman MM, Klerman GL, Markowitz JS, et al.: Suicidal ideation and suicide attempts in panic disorder and attacks. New England Journal of Medicine 321(18):1209–1214, 1989
Klerman GL, Weissman MM, Ouellette R, et al.: Panic attacks in the community. Social morbidity and health care utilization. JAMA 265(6):742–746, 1991
Kessler RC, McGonagle KA, Zhao S, et al.: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Archives of General Psychiatry 51:8–19, 1994
Kessler RC, Rubinow DR, Holmes C et al.: The epidemiology of DSM-III-R bipolar I disorder in a general population survey. Psychological Medicine 27:1079–1089, 1997
Feske U, Frank E, Mallinger AG, et al.: Anxiety as a correlate of response to the acute treatment of bipolar I disorder. American Journal of Psychiatry 157:956–962, 2000
Boylan KR, Bieling PJ, Marriott M et al.: Impact of comorbid anxiety disorders on outcome in a cohort of patients with bipolar disorder. Journal of Clinical Psychiatry 65:1106–1113, 2004
Harpold TL, Wozniak J, Kwon A, et al.: Examining the association between pediatric bipolar disorder and anxiety disorders in psychiatrically referred children and adolescents. Journal of Affective Disorders 88:19–26, 2005
Dickstein DP, Rich BA, Binstock AB, et al.: Comorbid anxiety in phenotypes of pediatric bipolar disorder. Journal of Child and Adolescent Psychopharmacology 15:534–548, 2005
Chen YW, Dilsaver SC: Comorbidity of panic disorder in bipolar illness: evidence from the epidemiologic catchment area survey. American Journal of Psychiatry 152:280–282, 1995
Doughty CJ, Wells JE, Joyce PR, et al.: Bipolar-panic disorder comorbidity within bipolar disorder families: a study of siblings. Bipolar Disorders 6:245–252, 2004
MacKinnon DF, Xu J, McMahon FJ, et al.: Bipolar disorder and panic disorder in families: an analysis of chromosome 18 data. American Journal of Psychiatry 155:829–831, 1998
Chen YW, Dilsaver SC: Comorbidity for obsessive-compulsive disorder in bipolar and unipolar disorders. Psychiatry Research 59:57–64, 1995
Fogarty F, Russel JM, Newman SC, et al.: Epidemiology of psychiatric disorders in Edmonton: mania. Acta Psychiatrica Scandinavica 376(Suppl):16–23, 1994
Perugi G, Akiskal HS, Lattanzi L, et al.: The high prevalence of “soft” bipolar (II) features in atypical depression. Comprehensive Psychiatry 39:63–71, 1998
Strakowski SM, Sax KW, McElroy SL, et al.: Course of psychiatric and substance abuse syndromes co-occurring with bipolar disorder after a first psychiatric hospitalization. Journal of Clinical Psychiatry 59:465–471, 1998
Pini S, Dell’Osso L, Mastrocinque C, et al.: Axis I comorbidity in bipolar disorder with psychotic features. British Journal of Psychiatry 175:467–471, 1999
Vieta E, Colom F, Corbella B, et al.: Clinical correlates of psychiatric comorbidity in bipolar I patients. Bipolar Disorders 3:253–258, 2001
Yerevanian BI, Koek RJ, Ramdev S: Anxiety disorders comorbidity in mood disorder subgroups: data from a mood disorders clinic. Journal of Affective Disorders 67:167–173, 2001
Altindag A, Yanik M, Nebioglu M: The comorbidity of anxiety disorders in bipolar I patients: prevalence and clinical correlates. Israel Journal of Psychiatry and Related Sciences 43:10–15, 2006
Coryell W, Endicott J, Andreasen N, et al.: Bipolar I, bipolar II, and nonbipolar major depression among the relatives of affectively ill probands. American Journal of Psychiatry 142:817–821, 1985
Swartz CM, Shen WW: Is episodic obsessive compulsive disorder bipolar? A report of four cases. Journal of Affective Disorders 56:61–66, 1999
Masi G, Perugi G, Toni C, et al.: Obsessive-compulsive bipolar comorbidity: focus on children and adolescents. Journal of Affective Disorders 78:175–183, 2004
Brown GR, McBride L, Bauer MS, et al.: Impact of childhood abuse on the course of bipolar disorder: a replication study in U.S. veterans. Journal of Affective Disorders 89:57–67, 2005
Goldberg JF, Garno JL: Development of posttraumatic stress disorder in adult bipolar patients with histories of severe childhood abuse. Journal of Psychiatric Research 39:595–601, 2005
Kennedy BL, Dhaliwal N, Pedley L, et al.: Post-traumatic stress disorder in subjects with schizophrenia and bipolar disorder. Journal of the Kentucky Medical Association 100:395–399, 2002
Pollack MH, Simon NM, Fagiolini A, et al.: Persistent posttraumatic stress disorder following September 11 in patients with bipolar disorder. Journal of Clinical Psychiatry 67:394–357, 2006
Otto MW, Perlman CA, Wernicke R, et al.: Posttraumatic stress disorder in patients with bipolar disorder: a review of prevalence, correlates, and treatment strategies. Bipolar Disorders 6:470–479, 2004
Baldassano CF, Marangell LB, Gyulai L, et al.: Gender differences in bipolar disorder: retrospective data from the first 500 STEP-BD participants. Bipolar Disorders 7:465–470, 2005
Henin A, Biederman J, Mick E, et al.: Psychopathology in the offspring of parents with bipolar disorder: a controlled study. Biological Psychiatry 58:554–561, 2005
Grant BF, Hasin DS, Blanco C et al.: The epidemiology of social anxiety disorder in the United States: results from the National Epidemiologic survey on Alcohol and Related Conditions. Journal of Clinical Psychiatry 66:1351–1361, 2005
Gaudiano BA, Miller IW: Anxiety disorder comorbidity in bipolar I disorder: relationship to depression severity and treatment outcome. Depression and Anxiety 21:71–77, 2005
Keller MB: Prevalence and impact of comorbid anxiety and bipolar disorder. Journal of Clinical Psychiatry 67(Suppl 1):5–7, 2006
Allen MH, Chessick CA, Miklowitz DJ, et al.: Contributors to suicidal ideation among bipolar patients with and without a history of suicide attempts. Suicide and Life Threatening Behavior 35:671–680, 2005
Young LT, Cooke RG, Robb JC, et al.: Anxious and non-anxious bipolar disorder. Journal of Affective Disorders 29:49–52, 1993
Perlis RH, Miyahara S, Marangell LB, et al.: Long-Term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biological Psychiatry 55(9):875–881, 2004
Otto MW, Simon NM, Wisniewski SR et al.: Prospective 12-month course of bipolar disorder in out-patients with and without comorbid anxiety disorders. British Journal of Psychiatry 189:20–25, 2006
Simon NM, Zalta AK, Otto MW, et al.: The association of comorbid anxiety disorders with suicide attempts and suicidal ideation in outpatients with bipolar diosorder. Journal Psychiatric Research 41:255–264, 2007
Simon NM, Otto MW, Wisniewski SR, et al.: Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). American Journal of Psychiatry 161:2222–2229, 2004
Matza LS, Rajagopalan KS, Thompson CL, et al.: Misdiagnosed patients with bipolar disorder: comorbidities, treatment patterns, and direct treatment costs. Journal of Clinical Psychiatry 66:1432–1440, 2005
Hollifield M, Mackey A, Davidson J: Integrating therapies for anxiety disorders. Psychiatric Annals 36:329–338, 2006
van der Kolk BA, Spinazzola J, Blaustein ME, et al.: A randomized clinical trial of eye movement desensitization and reprocessing (EMDR), fluoxetine, and pill placebo in the treatment of posttraumatic stress disorder: treatment effects and long-term maintenance. Journal of Clinical Psychiatry 68:37–46, 2007
Asnis GM, Kohn SR, Henderson M, et al.: SSRIs versus non-SSRIs in post-traumatic stress disorder: an update with recommendations. Drugs 64:383–404, 2004
Marshall RD, Beebe KL, Oldham M, et al.: Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. American Journal of Psychiatry 158(12):1982–1988, 2001
Tucker P, Zaninelli R, Yehuda R, et al.: Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. Journal of Clinical Psychiatry 62(11):860–868, 2001
Pollack MH, Lepola U, Kpenen H, et al.: A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depression and Anxiety 24(1):1–14, 2007
Pollack MH, Mangano R, Entsuah R, et al.: A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology (Berlin) 2007 (Epub ahead of print)
Shuurmans J, Comijs H, Emmelkamp PM, et al.: A randomized, controlled trial of the effectiveness of cognitive-behavioral therapy and sertraline versus a waitlist control group for anxiety disorders in older adults. American Journal of Geriatric Psychiatry 14:255–263, 2006
Kamijima K, Kuboki T, Kumano H, et al.: A placebo-controlled, randomized withdrawal study of sertraline for panic disorder in Japan. International Clinical Psychopharmacology 20(5):265–273, 2005
Stahl SM, Gergel I, Li D: Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry 64:1322–1327, 2003
Londborg PD, Wolkow R, Smith WT et al.: Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation. British Journal of Psychiatry 173:54–60, 1998
Oehrberg S, Christiansen PE, Behnke K, et al.: Paroxetine in the treatment of panic disorder: a randomized, double-blind, placebo-controlled study. British Journal of Psychiatry 167:374–379, 1995
Brawman-Mintzer O, Knapp RG, et al.: Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry 67(6):874–881, 2006
Goodman WK, Bose A, Wang Q: Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. Journal of Affective Disorders 87(2–3):161–167, 2005
Davidson JR, Bose A, Korotzer A, et al.: Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depression and Anxiety 19:234–240, 2004
Hedges DW, Brown BL, Shwalb DA, et al.: The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: a meta-analysis of double-blind, placebo-controlled trials. Journal of Psychopharmacology 21(1):102–111, 2007
Stein DJ, Andersen EW, Tonnoir B, et al.: Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Current Medical Research and Opinion 23:701–711, 2007
Pallanti S, Quercioli L, Koran LM: Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. Journal of Clinical Psychiatry 63:796–801, 2002
Montgomery SA, Kasper S, Stein DJ, et al.: Citalopram 20 mg, 40 mg, and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. International Clinical Psychopharmacology 16:75–86, 2001
Becker ME, Hertzberg MA, Moore SD, et al.: A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder. Journal of Clinical Psychopharmacology 27:193–197, 2007
El-Mallakh RS, Karippot A: Use of antidepressants to treat depression in bipolar disorder. Psychiatric Services 53:580–584, 2002
Ghaemi SN, Hsu DJ, Soldani F, et al.: Antidepressants in bipolar disorder: the case for caution. Bipolar Disorders 5(6):421–433, 2003
El-Mallakh RS, Karippot A: Chronic depression in bipolar disorder. American Journal of Psychiatry 163:1337–1341 (quiz on 1478), 2006
El-Mallakh RS, Karippot A: Antidepressant-associated chronic irritable dysphoria (ACID) in bipolar disorder. Journal of Affect Disorders 84:267–272, 2005
Kukopulos A, Caliari B, Tundo A, et al.: Rapid Cyclers, temperament, and antidepressants. Comprehensive Psychiatry 24:249–258, 1983
Altshuler LL, Post RM, Leverich GS, et al.: Antidepressant-induced mania and cycle acceleration: a controversy revisited. American Journal of Psychiatry 152:1130–1138, 1995
Simon NM, Otto MW, Weiss RD, et al.: Pharmacotherapy for bipolar disorder and comorbid conditions: baseline data from STEP-BD. Journal of Clinical Psychopharmacollogy 24:512–520, 2004
Lembke A, Miklowitz DJ, Otto MW, et al.: Psychosocial service utilization by patients with bipolar disorders: data from the first 500 participants in the Systematic Treatment Enhancement Program. Journal of Psychiatric Practice 10:81–87, 2004
Pande AC, Davidson JR, Jefferson JW, et al.: Treatment of social phobia with gabapentin: a placebo-controlled study. Journal of Clinical Psychopharmacology 19(4):341–348, 1999
Pande AC, Pollack MH, Crockatt J et al.: Placebo-controlled study of gabapentin treatment of panic disorder. Journal of Clinical Psychopharmacology 20(4):467–471, 2000
Sepede G, De Berardis D, Gambi F, et al.: Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial. Journal of Clinical Psychopharmacology 26:45–49, 2006
Hollifield M, Thompson PM, Ruiz JE, et al.: Potential effectiveness and safety of olanzapine in refractory panic disorder. Depression and Anxiety 21:33–40, 2005
Hirshfeld RM, Weisler RH, Raines SR, et al.: Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry 67:355–363, 2006
Bystritsky A, Ackerman DL, Rosen RM, et al.: Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. Journal of Clinical Psychiatry 65:565–568, 2004
Oruc L, Cavuljuga S: Olanzapine in treatment of patients with bipolar I disorder and panic comorbidity: a case study. Bosnian Journal of Basic Medical Science 3:67–69, 2003
Hamner MB, Robert S, Frueh C: Treatment-resistant posttraumatic stress disorder: strategies for intervention. CNS Spectrums 9:740–752, 2004
Keck PE Jr, McElroy SL, Friedman LM: Valproate and carbamazepine in the treatment of panic and posttraumatic stress disorders, withdrawal states, and behavioral dyscontrol syndromes. Journal of Clinical Psychopharmacology 12(1 Suppl):36S–41S, 1992
Munjack DJ, Croker B, Cabe D et al.: Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks. Journal of Clinical Psychopharmacology 9:22–27, 1989
Swinson RP, Pecknold JC, Kuch K: Psychopharmacological treatment of panic disorder and related states: a placebo controlled study of alprazolam. Progress in Neuropsychopharmacology and Biological Psychiatry 11:105–113, 1987
Chouinard G: The use of benzodiazepines in the treatment of manic-depressive illness. Journal of Clinical Psychiatry 49(Suppl):15–20, 1988
Valença AM, Nardi AE, Nascimento I, Mezzasalma MA, Lopes FL, Zin W: Double-blind clonazepam vs placebo in panic disorder treatment. Arquivos de Neuro-Psiquiatria 58(4):1025–1029, 2000
Seedat S, Stein MB: Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. Journal of Clinical Psychiatry 65(2):244–248, 2004
Clark RE, Xie H, Brunette MF: Benzodiazepine prescription practices and substance abuse in persons with severe mental illness. Journal of Clinical Psychiatry 65:151–155, 2004
Brunette MF, Noordsy DL, Xie H, et al.: Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders. Psychiatric Services 54:1395–1401, 2003
Weiss RD, Greenfield SF, Najavits LM, et al.: Medication compliance among patients with bipolar disorder and substance use disorder. Journal of Clinical Psychiatry 59:172–174, 1998
Turkington D, Gill P: Mania induced by lorazepam withdrawal: a report of two cases. Journal of Affective Disorders 17(1):93–95, 1989
Miller NS, Guttman JC: The integration of pharmacological therapy for comorbid psychiatric and addictive disorders. Journal of Psychoactive Drugs 29:249–254, 1997
Wilhelm FH, Roth WT: Acute and delayed effects of alprazolam on flight phobics during exposure. Behavior Research and Therapy 35:831–841, 1997
Gelpin E, Bonne O, Peri T, et al.: Treatment of recent trauma survivors with benzodiazepines: a prospective study. Journal of Clinical Psychiatry 57:390–394, 1996
Chouinard G, Labonte A, Fontaine R, et al.: New concepts in benzodiazepine therapy: rebound anxiety and new indications for the more potent benzodiazepines. Progress in Neuropsychopharmacology and Biological Psychiatry 7:669–673, 1983
Dusseldorp E, Spinhoven P, Bakker A, et al.: Which panic disorder patients benefit from which treatment: cognitive therapy or antidepressants? Psychotherapy and Psychosomatics 76(3):154–61, 2007
Anderson RA, Rees CS: Group versus individual cognitive-behavioral treatment for obsessive-compulsive disorder: a controlled trial. Behavior Research and Therapy 45(1):123–37, 2007
Linden M, Zubraegel D, Baer T, et al.: Efficacy of cognitive behaviour therapy in generalized anxiety disorders. Results of a controlled clinical trial (Berlin CBT-GAD Study). Psychotherapy and Psychosomatics 74:36–42, 2005
Blanchard EB, Hickling EJ, Devineni T, et al.: A controlled evaluation of cognitive behavioural therapy for posttraumatic stress in motor vehicle accident survivors. Behavior Research and Therapy 41(1):79–96, 2003
Mitte K: A meta-analysis of psycho- and pharmacotherapy in panic disorder with and without agoraphobia. Journal of Affective Disorders 88:27–45, 2005
Hollon SD, Stewart MO, Strunk D: Enduring effects for cognitive behavior therapy in the treatment of depression and anxiety. Annual Review of Psychology 57:285–315, 2006
Fava GA, Ruini C, Rafanelli C: Sequential treatment of mood and anxiety disorders. Journal of Clinical Psychiatry 66:1392–1400, 2005
Scott J, Paykel E, Morriss R, et al.: Cognitive behavioral therapy for severe and recurrent bipolar disorders: a randomized controlled trial. British Journal of Psychiatry 188:313–320, 2006
Bell JR, Mitchell PB, Corry JC, et al.: A randomized controlled trial of cognition therapy for bipolar disorder: focus on long-term change. Journal of Clinical Psychiatry 67:277–286, 2006
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
El-Mallakh, R.S., Hollifield, M. Comorbid Anxiety in Bipolar Disorder Alters Treatment and Prognosis. Psychiatr Q 79, 139–150 (2008). https://doi.org/10.1007/s11126-008-9071-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11126-008-9071-5